



04-25-07

11^W 1644

PTO/SB/21 (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

22 + 160
refs.

Application Number

10/529,835

Filing Date

October 6, 2003 (Int'l)

First Named Inventor

David L. SHELTON

Art Unit

1644

Examiner Name

Not Yet Assigned

Attorney Docket Number

514712000300

ENCLOSURES (Check all that apply)☐ Fee Transmittal Form☐ Fee Attached☐ Amendment/Reply☐ After Final☐ Affidavits/declaration(s)☐ Extension of Time Request☐ Express Abandonment Request☒ Information Disclosure Statement (3
pages)☐ Certified Copy of Priority
Document(s)☐ Reply to Missing Parts/
Incomplete Application☐ Reply to Missing Parts under
37 CFR 1.52 or 1.53☐ Drawing(s)☐ Licensing-related Papers☐ Petition☐ Petition to Convert to a
Provisional Application☐ Power of Attorney, Revocation
Change of Correspondence Address☐ Terminal Disclaimer☐ Request for Refund☐ CD, Number of CD(s) _____☐ Landscape Table on CD☐ After Allowance Communication
to TC☐ Appeal Communication to Board of
Appeals and Interferences☐ Appeal Communication to TC
(Appeal Notice, Brief, Reply Brief)☐ Proprietary Information☐ Status Letter☒ Other Enclosure(s) (please
Identify below):PTO/SB08a/b + copy (18 pages)
References (160)
Return Receipt Postcard

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name

MORRISON & FOERSTER LLP (Customer No. 25226)

Signature

Printed name

Jie Zhou

Date

April 23, 2007

Reg. No.

52,395

I hereby certify that this paper is being deposited with the U.S. Postal Service as Express Mail, Airbill Nos. EV 581427020 US (Box 1) and EV 581427033 US (Box 2), on the date shown below in boxes addressed to:
MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: April 23, 2007

Signature:

(Georgina Matos)


I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill Nos. EV 581427020 US (Box 1) and EV 581427033 US (Box 2), in boxes addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: April 23, 2007

Signature:

Georgina Matos
(Georgina Matos)

PATENT
Docket No. 514712000300



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Patent Application of:
David L. SHELTON

Serial No.: 10/529,835

International Filing Date: October 6, 2003

For: METHODS FOR TREATING CARDIAC
ARRHYTHMIA AND PREVENTING
DEATH DUE TO CARDIAC
ARRHYTHMIA USING NGF
ANTAGONISTS

Examiner: Not Yet Assigned

Group Art Unit: 1644

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicant submits for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

Applicant would like to bring to the Examiner's attention the co-pending applications listed below:

Application Serial No. 10/682,638 filed on October 8, 2003, by Shelton et al.,

Application Serial No. 10/791,162 filed on March 1, 2004, by Shelton et al., and

Application Serial No. 11/104,248 filed on April 11, 2005, by Rosenthal et al.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of ___ is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of ___ is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.

Applicant would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.


The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has

been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 514712000300.

Dated: April 23, 2007

Respectfully submitted,

By 
Jie Zhou

Registration No.: 52,395
MORRISON & FOERSTER LLP
755 Page Mill Road
Palo Alto, California 94304-1018
(650) 813-5922



ALTERNATIVE TO PTO/SB/08a/b (07-05)

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/529,835
				Filing Date	(Intl.) October 6, 2003
				First Named Inventor	David L. SHELTON
				Art Unit	1644
				Examiner Name	Not Yet Assigned
Sheet	1	of	9	Attorney Docket Number	514712000300

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	1.	US-2001/0046959-A1	11-29-2001	Buchovich et al.	
	2.	US-2002/0045669-A1	04-18-2002	Bergeron, Jr.	
	3.	US-2002/0058970-A1	05-16-2002	Chen	
	4.	US-2004/0131615-A1	07-08-2004	Shelton et al.	
	5.	US-2004/0237124-A1	11-25-2004	Pons et al.	
	6.	US-2004/0253244-A1	12-16-2004	Shelton et al.	
	7.	US-3,773,919	11-20-1973	Boswell et al.	
	8.	US-4,485,045	11-27-1984	Regen	
	9.	US-4,544,545	10-01-1985	Ryan et al.	
	10.	US-4,777,127	10-11-1988	Suni et al.	
	11.	US-4,816,567	03-28-1989	Cabilly et al.	
	12.	US-5,013,556	05-07-1991	Woodle et al.	
	13.	US-5,219,740-A	06-15-1993	Miller et al.	
	14.	US-5,342,942-A	08-30-1994	Jaen et al.	
	15.	US-5,422,120-A	06-06-1995	Kim	
	16.	US-5,500,362-A	03-19-1996	Robinson et al.	
	17.	US-5,530,101-A	06-25-1996	Queen et al.	
	18.	US-5,565,332-A	10-15-1996	Hoogenboom et al.	
	19.	US-5,580,717-A	12-03-1996	Dower et al.	
	20.	US-5,580,859-A	12-03-1996	Felgner et al.	
	21.	US-5,585,089-A	12-17-1996	Queen et al.	
	22.	US-5,693,761-A	12-02-1997	Queen et al.	
	23.	US-5,693,762-A	12-02-1997	Queen et al.	
	24.	US-5,733,743-A	03-31-1998	Johnson et al.	
	25.	US-5,766,863-A	06-16-1998	Godowski et al.	
	26.	US-5,807,715-A	09-15-1998	Morrison et al.	
	27.	US-5,814,482-A	09-29-1998	Dubensky, Jr. et al.	
	28.	US-5,844,092-A	12-01-1998	Presta et al.	
	29.	US-5,866,692-A	02-02-1999	Shitara et al.	
	30.	US-5,877,016-A	03-02-1999	Presta et al.	
	31.	US-5,891,650-A	04-06-1999	Godowski et al.	
	32.	US-5,981,568-A	11-09-1999	Kunz et al.	
	33.	US-5,997,867-A	12-07-1999	Waldmann et al.	
	34.	US-6,017,878-A	01-25-2000	Saragovi et al.	
	35.	US-6,054,297-A	04-25-2000	Carter et al.	
	36.	US-6,127,401-A	10-03-2000	Singh et al.	
	37.	US-6,153,189-A	11-28-2000	Presta et al.	
	38.	US-6,180,370-B1	01-30-2001	Queen et al.	
	39.	US-6,180,377-B1	01-30-2001	Morgan et al.	
	40.	US-6,210,671-B1	04-03-2001	Co	
	41.	US-6,265,150-B1	07-24-2001	Terstappen et al.	
	42.	US-6,291,247-B1	09-18-2001	Riopelle et al.	
	43.	US-6,306,849-B1	10-23-2001	Hudkins et al.	
	44.	US-6,331,415-B1	12-18-2001	Cabilly et al.	
	45.	US-6,350,861-B1	02-26-2002	Co et al.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

PA- 1122543

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/529,835
				Filing Date	(Intl.) October 6, 2003
				First Named Inventor	David L. SHELTON
				Art Unit	1644
				Examiner Name	Not Yet Assigned
Sheet	2	of	9	Attorney Docket Number	514712000300

46.	US-6,351,668-B1	02-26-2002	Chen	
47.	US-6,353,757-B2	03-05-2002	Chen	
48.	US-6,359,130-B1	03-19-2002	Singh et al.	
49.	US-6,376,471-B1	04-23-2002	Lawrence, III et al.	
50.	US-6,413,942-B1	07-02-2002	Felgner et al.	
51.	US-6,436,908-B1	08-20-2002	Koch et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†
		Country Code ² -Number ³ -Kind Code ⁵ (if known)	MM-DD-YYYY			
	52.	EP-0 345 242-A2, A3	12-06-1989	SmithKline Biologicals, S.A.	Translation of Abstract Only	
	53.	EP-0 519 596-A1, B1	12-23-2005	Merck & Co. Inc. et al.		
	54.	EP-0 524 968-A1, B1	02-03-1993	Research Development Foundation		
	55.	GB-2 200 651-A	08-10-1988	Ayad		
	56.	WO-87/04462-A1	07-30-1987	CellTech Limited et al.		
	57.	WO-89/09225-A1	10-05-1989	The Regents of the University of California		
	58.	WO-90/07936-A1	07-26-1990	Chiron Corporation		
	59.	WO-90/11092-A1	10-04-1990	Vical, Inc. et al.		
	60.	WO-91/00904-A1	01-24-1991	Smith-Kline Beckman Corporation		
	61.	WO-91/02805-A2, A3	03-07-1991	Viagene, Inc.		
	62.	WO-91/14445-A1	10-03-1991	Research Development Foundation		
	63.	WO-93/03769-A1	03-04-1993	U.S. Secretary of the Department of Health and Human Services		
	64.	WO-93/06213-A1	04-01-1993	Medical Research Council et al.		
	65.	WO-93/10218-A1	05-27-1993	U.S. Secretary of the Department of Health and Human Services et al.		
	66.	WO-93/11230-A1	06-10-1993	Dynal AS		
	67.	WO-93/19191-A1	09-30-1993	Centre National de la Recherche Scientifique et al.	Translation of Abstract Only	
	68.	WO-93/25234-A1	12-23-1993	The Regents of the University of California		
	69.	WO-93/25698-A1	12-23-1993	U.S. Secretary of the Department of Health and Human Services		
	70.	WO-94/03622-A1	02-17-1994	Imperial College of Science, Technology & Medicine		
	71.	WO-94/12649-A2, A3	06-09-1994	Genzyme Corporation		
	72.	WO-94/13274-A1	06-23-1994	Abbott Laboratories		
	73.	WO-94/23697-A1	10-27-1994	Depotech Corporation		
	74.	WO-94/28938-A1	12-22-1994	The Regents of the University of Michigan		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

PA- 1122543

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/529,835
				Filing Date	(Intl.) October 6, 2003
				First Named Inventor	David L. SHELTON
				Art Unit	1644
				Examiner Name	Not Yet Assigned
Sheet	3	of	9	Attorney Docket Number	514712000300

75.	WO-95/00655-A1	01-05-1995	McMaster University	
76.	WO-95/07994-A2, A3	03-23-1995	Viagene, Inc.	
77.	WO-95/11984-A2, A3	05-04-1995	Canji, Inc.	
78.	WO-95/13796-A1	05-26-1995	Depotech Corporation	
79.	WO-95/30763-A2, A3	11-16-1995	Viagene, Inc.	
80.	WO-96/17072-A2, A3	06-06-1996	Chiron Viagene, Inc.	
81.	WO-97/15593-A1	05-01-1997	Queen's University at Kingston	
82.	WO-97/21732-A1	06-19-1997	McGill University	
83.	WO-97/42338-A1	11-13-1997	Chiron Corporation	
84.	WO-98/06048-A2	02-12-1998	Queen's University at Kingston	
85.	WO-98/17278-A1	04-30-1998	Allelix Biopharmaceuticals Inc.	
86.	WO-00/53211-A2, A3	09-14-2000	University of Southern California	
87.	WO-00/69829-A1	11-23-2000	Queen's University at Kingston	
88.	WO-00/73344-A2, A3	12-07-2000	SIRS Societa' Italiana per la Ricerca Scientifica SRL	
89.	WO-01/27160-A1	04-19-2001	Applied Molecular Evolution, Inc. et al.	
90.	WO-01/62334-A2, A3	08-30-2001	Cedars-Sinai Medical Center	
91.	WO-01/64247-A2, A3	09-07-2001	Cephalon, Inc.	
92.	WO-01/78698-A2, A3	10-25-2001	Warner-Lambert Co.	
93.	WO-02/15924-A1	02-28-2002	The University of Bristol	
94.	WO-02/17914-A2, A3	03-07-2002	Cephalon, Inc.	
95.	WO-02/20479-A1	03-14-2002	Glaxo Group Ltd.	
96.	WO-2004/032870-A2, A3	04-22-2004	Rinat Neuroscience Corp.	
97.	WO-2004/058184-A2, A3	07-15-2004	Rinat Neuroscience Corp.	
98.	WO-2004/073653-A2, A3	09-02-2004	Rinat Neuroscience Corp.	
99.	WO-2004/096122-A2, A3	11-04-2004	Rinat Neuroscience Corp.	
100.	WO-2005/000194-A2, A3	01-06-2005	Rinat Neuroscience Corp.	

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	101.	Abe, T. et al. (January 7, 1997). "Protective Role of Nerve Growth Factor Against Postischemic Dysfunction of Sympathetic Coronary Innervation," <i>Circulation</i> 95(1):213-220.		
	102.	American Chemical Society (1987-1991). <u>Chemical Abstracts, 12th Collective Index, Chemical Substances, Volumes 106-115, page 34237CS, column 3, lines 5-7.</u>		
	103.	American Chemical Society (1987-1991). <u>Chemical Abstracts, 12th Collective Index, Chemical Substances, Volumes 106-115, page 34237CS, column 3, lines 55-60.</u>		
Examiner Signature				Date Considered

PA- 1122543

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/529,835
				Filing Date	(Intl.) October 6, 2003
				First Named Inventor	David L. SHELTON
				Art Unit	1644
				Examiner Name	Not Yet Assigned
Sheet	4	of	9	Attorney Docket Number	514712000300

104.	American Chemical Society (1987-1991). <u>Chemical Abstracts, 12th Collective Index, Chemical Substances, Volumes 106-115, page 34237CS, column 3, lines 66-69.</u>
105.	American Chemical Society (1987-1991). <u>Chemical Abstracts, 12th Collective Index, Chemical Substances, Volumes 106-115, page 34238CS, column 1, lines 41-44.</u>
106.	American Chemical Society (1987-1991). <u>Chemical Abstracts, 12th Collective Index, Chemical Substances, Volumes 106-115, page 34238CS, column 2, lines 25-27.</u>
107.	American Chemical Society (1987-1991). <u>Chemical Abstracts, 12th Collective Index, Chemical Substances, Volumes 106-115, page 34238CS, column 2, lines 32-33.</u>
108.	American Chemical Society (1987-1991). <u>Chemical Abstracts, 12th Collective Index, Chemical Substances, Volumes 106-115, page 34239CS, column 3, lines 48-50.</u>
109.	American Chemical Society (1987-1991). <u>Chemical Abstracts, 12th Collective Index, Chemical Substances, Volumes 106-115, page 34239CS, column 3, lines 52-53.</u>
110.	Armour, K. L. et al. (1999). "Recombinant Human IgG Molecules Lacking Fcγ Receptor I Binding and Monocyte Triggering Activities," <i>Eur. J. Immunol.</i> 29:2613-2624.
111.	Bibel, M. et al. (December 1, 2000). "Neurotrophins: Key Regulators of Cell Fate and Cell Shape in the Vertebrate Nervous System," <i>Genes Dev.</i> 14(23):2919-2937.
112.	Borsani, G. et al. (1990). "cDNA Sequence of Human β-NGF," <i>Nuc. Acids Res.</i> 18(13):4020.
113.	Brown, B.A. et al. (July 1, 1987). "Tumor-Specific Genetically Engineered Murine/Human Chimeric Monoclonal Antibody," <i>Cancer Res.</i> 47:3577-3583.
114.	Buchman, V.L. et al. (1993). "Different Neurotrophins are Expressed and Act in a Developmental Sequence to Promote the Survival of Embryonic Sensory Neurons," <i>Development</i> 118:989-1001.
115.	Buck, D.W. et al. (April 1982). "Monoclonal Antibodies Specific For Cell Culture Mycoplasmas," <i>In Vitro</i> 18(4):377-381.
116.	Cao, J-M. et al. (April 14, 2000). "Nerve Sprouting and Sudden Cardiac Death," <i>Circulation Research</i> 86:816-821.
117.	Cao, J-M. et al. (April 25, 2000). "Relationship Between Regional Cardiac Hyperinnervation and Ventricular Arrhythmia," <i>Circulation</i> 101:1960-1969.
118.	Carrió, I. (July 2001). "Cardiac Neurotransmission Imaging," <i>J. Nuc. Med.</i> , 42(7):1062-1076.
119.	Chao, M.V. et al. (April 25, 1986). "Gene Transfer and Molecular Cloning of the Human NGF Receptor," <i>Science</i> 232:518-521.
120.	Chen, P-S. et al. (2001). "Sympathetic Nerve Sprouting, Electrical Remodeling and the Mechanisms of Sudden Cardiac Death," <i>Cardiovascular Research</i> 50:409-416.
121.	Chiou, H.C. et al. (1994). "In Vivo Gene Therapy via Receptor-Mediated DNA Delivery," <i>In Gene Therapeutics: Methods and Applications of Direct Gene Transfer</i> J.A. Wolff, ed. Birkhäuser, pp. 143-156.
122.	Chun, L.L.Y. et al. (1977). "Role of Nerve Growth Factor in the Development of Rat Sympathetic Neurons in Vitro," <i>The Journal of Cell Biology</i> 75:705-711.
123.	Clackson, T. et al. (August 15, 1991). "Making Antibody Fragments Using Phage Display Libraries," <i>Nature</i> 352:624-628.
124.	Connelly, S. et al. (February 1995). "In Vivo Gene Delivery and Expression of Physiological Levels of Functional Human Factor VIII in Mice," <i>Human Gene Therapy</i> 6:185-193.
125.	Crowley, C. et al. (March 25, 1994). "Mice Lacking Nerve Growth Factor Display Perinatal Loss of Sensory and Sympathetic Neurons yet Develop Basal Forebrain Cholinergic Neurons," <i>Cell</i> 76:1001-1011.
126.	Curiel, D.T. et al. (1992). "High-Efficiency Gene Transfer Mediated by Adenovirus Coupled to DNA-Polylysine Complexes," <i>Hum. Gene Ther.</i> 3:147-154.
127.	Cutilletta, A.F. et al. (April 1977). "Development of Left Ventricular Hypertrophy in Young Spontaneously Hypertensive Rats After Peripheral Sympathectomy," <i>Circulation Research</i> 40(4):428-434.

Examiner Signature	Date Considered
--------------------	-----------------

PA-1122543

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/529,835
				Filing Date	(Intl.) October 6, 2003
				First Named Inventor	David L. SHELTON
				Art Unit	1644
				Examiner Name	Not Yet Assigned
Sheet	5	of	9	Attorney Docket Number	514712000300

128.	Daugherty, B.L. et al. (1991). "Polymerase Chain Reaction Facilitates the Cloning, CDR-Grafting, and Rapid Expression of a Murine Monoclonal Antibody Directed Against the CD18 Component of Leukocyte Integrins," <i>Nucl. Acids Res.</i> 19(9):2471-2476.
129.	Eide, F.F. et al. (May 15, 1996). "Naturally Occurring Truncated trkB Receptors Have Dominant Inhibitory Effects on Brain-Derived Neurotrophic Factor Signaling," <i>J. Neurosci.</i> 16(10):3123-3129.
130.	Eppstein, D.A. et al. (June 1985). "Biological Activity of Liposome-Encapsulated Murine Interferon γ is Mediated by a Cell Membrane Receptor," <i>Proc. Natl. Acad. Sci. USA</i> 82:3688-3692.
131.	Esler, M. et al. (2000). "Sympathetic Nervous System Activation in Essential Hypertension, Cardiac Failure and Psychosomatic Heart Disease," <i>J. Cardiovascular Pharmacol.</i> 35 (Suppl. 4):S1-S7.
132.	Estorch, M. et al. (June 1999). "Sympathetic Reinnervation of Cardiac Allografts Evaluated by 123 I-MIBG Imaging," <i>J. Nucl. Med.</i> 40(6):911-916.
133.	Findeis, M.A. et al. (May 1993). "Targeted Delivery of DNA for Gene Therapy Via Receptors," <i>Trends Biotechnol.</i> 11:202-205.
134.	Fogel, R.I. et al. (2000). "Management of Malignant Ventricular Arrhythmias and Cardiac Arrest," <i>Crit. Care Med.</i> 28(10-Suppl.):N165-N169.
135.	GenBank Accession No. L17077, "The Use of the RACE Method to Clone Hybridoma cDNA When V Region Primers Fail," created on February 7, 1995, located at < http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=310168 >, last visited on March 18, 2004, two pages.
136.	GenBank Accession No. L17078, "The Use of the RACE Method to Clone Hybridoma cDNA When V Region Primers Fail," created on February 7, 1995, located at < http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=310169 >, last visited on March 18, 2004, two pages.
137.	GenBank Accession No. NM_002506, "Histamine Enhances the Production of Nerve Growth Factor in Human Keratinocytes," created on December 23, 2003, located at < http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=4505390 >, last visited on June 11, 2004, four pages.
138.	GenBank Accession No. U39608, "Two Distinct Monoclonal Antibodies Raised Against Mouse Beta Nerve Growth Factor: Generation of Bi-Specific Anti-Nerve Growth Factor Anti-Horseradish Peroxidase Antibodies for Use in a Homogenous Enzyme Immunoassay," created on March 25, 1999, located at < http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=4096751 >, last visited on March 18, 2004, two pages.
139.	GenBank Accession No. U39609, "Two Distinct Monoclonal Antibodies Raised Against Mouse Beta Nerve Growth Factor: Generation of Bi-Specific Anti-Nerve Growth Factor Anti-Horseradish Peroxidase Antibodies for Use in a Homogenous Enzyme Immunoassay," created January 28, 1999, located at < http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=4096753 >, last visited on March 18, 2004, two pages.
140.	Graboyes, T.B. et al. (September 1982). "Long-Term Survival of Patients With Malignant Ventricular Arrhythmia Treated With Antiarrhythmic Drugs," <i>Am. J. Cardiol.</i> 50:437-443.
141.	Griffiths, A.D. et al. (1993). "Human Anti-Self Antibodies with High Specificity From Phage Display Libraries," <i>EMBO J.</i> 12(2):725-734.
142.	Gu, Y. et al. (October 1994). "Rapid Increase in NGF-A mRNA After Ischemia/Reperfusion and Preconditioning in Rat Heart," <i>Circulation, Abstracts from the 67th Scientific Sessions, Dallas, TX, November 14 -17, 1994</i> , 90(4 - pt. 2):I-249. Abstract No. 1338.
143.	Hasan, W. et al. (October 23, 2004). "Nerve Growth Factor May Regulate Sympathetic Hyperinnervation in the Peri-Infarct Myocardium," Program No. 39.6, 2004 Abstract

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

PA-1122543

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/529,835
				Filing Date	(Intl.) October 6, 2003
				First Named Inventor	David L. SHELTON
				Art Unit	1644
				Examiner Name	Not Yet Assigned
Sheet	6	of	9	Attorney Docket Number	514712000300

		<i>Viewer/Itinerary Planner</i> , Washington, DC: Society for Neuroscience, one page.	
144.		Hassankhani, A. et al. (May 1995). "Overexpression of NGF Within the Heart of Transgenic Mice Causes Hyperinnervation, Cardia Enlargement, and Hyperplasia of Ectopic Cells," <i>Dev. Biol.</i> 169(1):309-321.	
145.		Heath, B.M. et al. (November 1, 1998). "Overexpression of Nerve Growth Factor in the Heart Alters Ion Channel Activity and β -Adrenergic Signalling in an Adult Transgenic Mouse," <i>The Journal of Physiology</i> 512.3:779-791.	
146.		Hiltunen, J.O. et al. (2001). "Nerve Growth Factor and Brain-Derived Neurotrophic Factor mRNAs are Regulated in Distinct Cell Populations of Rat Heart After Ischaemia and Reperfusion," <i>J. Pathol.</i> 194:247-253.	
147.		Hongo, J. S. et al. (2000). "Antibody Binding Regions on Human Nerve Growth Factor Identified by Homolog- and Alanine-Scanning Mutagenesis," <i>Hybridoma</i> 19(3):215-227.	
148.		Huang, E.J. et al. (2001). "Neurotrophins: Roles in Neuronal Development and Function," <i>Annu. Rev. Neurosci.</i> 24:677-736.	
149.		Hwang, K.J. et al. (July 1980). "Hepatic Uptake and Degradation of Unilamellar Sphingomyelin/Cholesterol Liposomes: A Kinetic Study," <i>Proc. Natl. Acad. Sci. USA</i> 77(7):4030-4034.	
150.		Johnson, K.S. et al. (1993). "Human Antibody Engineering," <i>Current Opinion in Structural Biology</i> 3:564-571.	
151.		Jolly, D. (1994). "Viral Vector Systems for Gene Therapy," <i>Cancer Gene Therapy</i> 1(1):51-64.	
152.		Jones, P.T. et al. (May 29, 1986). "Replacing the Complementarity-Determining Regions in a Human Antibody With Those From a Mouse," <i>Nature</i> 321:522-525.	
153.		Kaplitt, M.G. et al. (October 1994). "Long-Term Gene Expression and Phenotypic Correction Using Adeno-Associated Virus Vectors in the Mammalian Brain," <i>Nature Genetics</i> 8:148-153.	
154.		Karlsson, R. et al. (1994). "Kinetic and Concentration Analysis Using BIA Technology," <i>Methods: A Companion to Methods in Enzymology</i> 6(2):99-110.	
155.		Kimura, O. et al. (1994). "Retroviral Delivery of DNA into the Livers of Transgenic Mice Bearing Premalignant and Malignant Hepatocellular Carcinomas," <i>Human Gene Therapy</i> 5:845-852.	
156.		Klein, R. et al. (May 18, 1990). "The <i>trkB</i> Tyrosine Protein Kinase Gene Codes for a Second Neurogenic Receptor That Lacks the Catalytic Kinase Domain," <i>Cell</i> 61:647-656.	
157.		Knüsel, B. et al. (September 1991). "K-252b Is a Selective and Nontoxic Inhibitor of Nerve Growth Factor Action on Cultured Brain Neurons," <i>J. Neurochemistry</i> 57(3):955-962.	
158.		Knüsel, B. et al. (1992). "K-252b Selectively Potentiates Cellular Actions and <i>trk</i> Tyrosine Phosphorylation Mediated by Neurotrophin-3," <i>J. Neurochemistry</i> 59:715-722.	
159.		Kohler, B. et al. (August 7, 1975). "Continuous Cultures of Fused Cells Secreting Antibody of Predetermined Specificity," <i>Nature</i> 256:495-497.	
160.		Koizumi, S. et al. (February 1988). "K-252a: A Specific Inhibitor of the Action of Nerve Growth Factor on PC12 Cells," <i>J. Neuroscience</i> 8(2):715-721.	
161.		Krenz, N.R. et al. (September 1, 1999). "Neutralizing Intraspinal Nerve Growth Factor Blocks Autonomic Dysreflexia Caused by Spinal Cord Injury," <i>J. Neuroscience</i> 19(17):7405-7414.	
162.		Lai, A.C. et al. (December 2000). "Colocalization of Tenascin and Sympathetic Nerves in a Canine Model of Nerve Sprouting and Sudden Cardiac Death," <i>J. Cardiovasc. Electrophysiol.</i> 11(12):1352-1354.	
163.		Lamballe, F. et al. (1993). " <i>trkC</i> Encodes Multiple Neurotrophin-3 Receptors with Distinct Biological Properties and Substrate Specificities," <i>EMBO J.</i> 12(8):3083-3094.	
164.		Levi-Montalcini, R. et al. (July 1968). "Nerve Growth Factor," <i>Physiol. Rev.</i> 48(3):534-569.	
165.		Li, Y-X. et al. (September 1998). "Expression of a Dominant Negative TrkB Receptor, T1, Reveals a Requirement For Presynaptic Signaling in BDNF-Induced Synaptic Potentiation in Cultured Hippocampal Neurons," <i>Proc. Natl. Acad. Sci. USA</i> 95:10884-10889.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

PA- 1122543

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/529,835
				Filing Date	(Intl.) October 6, 2003
				First Named Inventor	David L. SHELTON
				Art Unit	1644
				Examiner Name	Not Yet Assigned
Sheet	7	of	9	Attorney Docket Number	514712000300

166.	Lindsay, R.M. et al. (January 26, 1989). "Nerve Growth Factor Regulates Expression of Neuropeptide Genes in Adult Sensory Neurons," <i>Nature</i> 337:362-364.	
167.	Liu, Q-Y. et al. (1998). "Sympathetic Innervation Modulates Repolarizing K ⁺ Currents in Rat Epicardial Myocytes," <i>Am. J. Physiol.</i> 274(3 Pt. 2):H915-H922.	
168.	Liu, Z.Z. et al. (November 15, 1997). "Critical Role of TrkB and Brain-Derived Neurotrophic Factor in the Differentiation and Survival of Retinal Pigment Epithelium," <i>J. Neurosci.</i> 17(22):8749-8755.	
169.	LoBuglio, A.F. et al. (June 1989). "Mouse/Human Chimeric Monoclonal Antibody in Man: Kinetics and Immune Response," <i>Proc. Natl. Acad. Sci. USA</i> 86:4220-4224.	
170.	Lonberg, N. et al. (1995). "Human Antibodies From Transgenic Mice," <i>Int. Rev. Immunol.</i> 13:65-93.	
171.	Mahato, R.I. et al. (1997). "Cationic Lipid-Based Gene Delivery Systems: Pharmaceutical Perspectives," <i>Pharm Res.</i> 14(7):853-859.	
172.	Marks, J.D. et al. (1991). "By-Passing Immunization: Human Antibodies From V-Gene Libraries Displayed on Phage," <i>J. Mol. Biol.</i> 222:581-597.	
173.	Marks, J.D. et al. (July 1992). "By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling," <i>Bio/Technol.</i> 10:779-783.	
174.	McCafferty, J. et al. (December 6, 1990). "Phage Antibodies, Filamentous Phage Displaying Antibody Variable Domains," <i>Nature</i> 348:552-554.	
175.	McDonald, N.Q. et al. (December 5, 1991). "New Protein Fold Revealed by a 2.3-Å Resolution Crystal Structure of Nerve Growth Factor," <i>Nature</i> 354(6352):411-414.	
176.	Minardo, J.D. et al. (October 1988). "Scintigraphic and Electrophysiological Evidence of Canine Myocardial Sympathetic Denervation and Reinnervation Produced by Myocardial Infarction or Phenol Application," <i>Circulation</i> 78(4):1008-1019.	
177.	Morrison, S.L. et al. (November 1984). "Chimeric Human Antibody Molecules: Mouse Antigen-Binding Domains with Human Constant Region Domains," <i>Proc. Natl. Acad. Sci. USA</i> 81:6851-6855.	
178.	Osman, A.F. et al. (2002). "T Wave Alternans for Ventricular Arrhythmia Risk Stratification," <i>Current Opinion in Cardiology</i> 17:1-5.	
179.	Peeters, K. et al. (2001). "Production of Antibodies and Antibody Fragments in Plants," <i>Vaccine</i> 19:2756-2761.	
180.	Philip, R. et al. (April 1994). "Efficient and Sustained Gene Expression in Primary T Lymphocytes and Primary and Cultured Tumor Cells Mediated by Adeno-Associated Virus Plasmid DNA Complexed to Cationic Liposomes," <i>Mol. Cell Biol.</i> 14(4):2411-2418.	
181.	Podrid, P.J. et al. (August 1990). "Role of the Sympathetic Nervous System in the Genesis of Ventricular Arrhythmia," <i>Circulation</i> 82(2-Suppl I):I-103 thru I-113.	
182.	Pollock, D.P. et al. (1999). "Transgenic Milk as a Method For the Production of Recombinant Antibodies," <i>J. Immunol. Methods</i> 231:147-157.	
183.	Priori, S.G. et al. (July 1988). "Ventricular Fibrillation Induced by the Interaction Between Acute Myocardial Ischemia and Sympathetic Hyperactivity: Effect of Nifedipine," <i>Am. Heart J.</i> 116:37-43.	
184.	Priori, S.G. et al. (2001). "Task Force on Sudden Cardiac Death of the European Society of Cardiology," <i>European Heart Journal</i> 22:1374-1450.	
185.	Riechmann, L. et al. (March 24, 1988). "Reshaping Human Antibodies for Therapy," <i>Nature</i> 332:323-327.	
186.	RNA-TEC NV (2002). "http://www.rna-tec.com/repair.html," located at <http://www.archive.org/web/20030210181600/http://www.rna-tec.com/>, last visited on January 25, 2007, four pages.	
187.	Ruberti, F. et al. (1993). "Cloning and Expression of an Anti-Nerve Growth Factor (NGF) Antibody for Studies Using the Neuroantibody Approach," <i>Cellular and Molecular Neurobiology</i>	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

PA-1122543

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/529,835
				Filing Date	(Intl.) October 6, 2003
				First Named Inventor	David L. SHELTON
				Art Unit	1644
				Examiner Name	Not Yet Assigned
Sheet	8	of	9	Attorney Docket Number	514712000300

		13(5):559-568.	
188.	Schmid, H. et al. (March 1999). "Heterogeneous Cardiac Sympathetic Denervation and Decreased Myocardial Nerve Growth Factor in Streptozotocin-Induced Diabetic Rats," <i>Diabetes</i> 48:603-608.		
189.	Schuijers, J.A. et al. (1986). "Effect of Hypoxemia on Plasma Catecholamines in Intact and Immunosympathectomized Fetal Lambs," <i>Am. J. Physiol.</i> 251(5 Pt. 2):R893-R900.		
190.	Sevarino, K.A. et al. (January 15, 1988). "Biosynthesis of Thyrotropin-Releasing Hormone by a Rat Medullary Thyroid Carcinoma Cell Line," <i>J. Biol. Chem.</i> 263(2):620-623.		
191.	Shaw, D.R. et al. (June 15, 1987). "Characterization of a Mouse/Human Chimeric Monoclonal Antibody (17-1A) To A Colon Cancer Tumor-Associated Antigen," <i>J. Immunol.</i> 138(12):4534-4538.		
192.	Smyene, R.J. et al. (March 17, 1994). "Severe Sensory and Sympathetic Neuropathies in Mice Carrying a Disrupted Trk/NGF Receptor Gene," <i>Nature</i> 368:246-249.		
193.	Stanton, M.S. et al. (November 15, 1989). "Regional Sympathetic Denervation After Myocardial Infarction in Humans Detected Noninvasively Using I-123-Metaiodobenzylguanidine," <i>J. Am. Coll. Cardiol.</i> 14(6):1519-1526.		
194.	Steinberg, S.F. et al. (1991). "Beta Adrenergic Modulation of Cardiac Rhythm in a Rat Model of Altered Sympathetic Neural Development," <i>J. Mol. Cell. Cardiol.</i> 23 (Suppl. 1):47-52.		
195.	Supplementary European Search Report mailed January 17, 2006, for EP Application No. 03776238.2, filed October 6, 2003, three pages.		
196.	Tsoufas, P. et al. (May 1993). "The Rat <i>trkC</i> Locus Encodes Multiple Neurogenic Receptors That Exhibit Differential Response to Neurotrophin-3 in PC12 Cells," <i>Neuron</i> 10:975-990.		
197.	Ullrich, A. et al. (June 30, 1983). "Human β -Nerve Growth Factor Gene Sequence Highly Homologous to That of Mouse," <i>Nature</i> 303:821-825.		
198.	Urfer, R. et al. (1997). "Specificity Determinants in Neurotrophin-3 and Design of Nerve Growth Factor-Based <i>trkC</i> Agonists by Changing Central β -Strand Bundle Residues to Their Neurotrophin-3 Analogs," <i>Biochem.</i> 36:4775-4781.		
199.	Valenzuela, D.M. et al. (May 1993). "Alternative Forms of Rat <i>TrkC</i> With Different Functional Capabilities," <i>Neuron</i> 10:963-974.		
200.	Vanoli, E. et al. (1990). "Sympathetic - Parasympathetic Interaction and Sudden Death," <i>Basic Res. Cardiol.</i> 85:305-321.		
201.	Verhoeyen, M. et al. (March 25, 1988). "Reshaping Human Antibodies: Grafting an Antilysozyme Activity," <i>Science</i> 239:1534-1536.		
202.	Waterhouse, P. et al. (1993). "Combinatorial Infection and <i>in vivo</i> Recombination: A Strategy for Making Large Phage Antibody Repertoires," <i>Nucl. Acids Res.</i> 21(9):2265-2266.		
203.	Wiesmann, C. et al. (September 9, 1999). "Crystal Structure of Nerve Growth Factor in Complex with the Ligand-Binding Domain of the <i>TrkA</i> Receptor," <i>Nature</i> 401:184-188.		
204.	Winter, G. et al. (January 24, 1991). "Man-Made Antibodies," <i>Nature</i> 349:293-299.		
205.	Winter, G. et al. (1994). "Making Antibodies by Phage Display Technology," <i>Annu. Rev. Immunol.</i> 12:433-455.		
206.	Woffendin, C. et al. (November 1994). "Nonviral and Viral Delivery of a Human Immunodeficiency Virus Protective Gene into Primary Human T Cells," <i>Proc. Natl. Acad. Sci. USA</i> 91:11581-11585.		
207.	Wu, C.H. et al. (October 15, 1989). "Targeting Genes: Delivery and Persistent Expression of a Foreign Gene Driven by Mammalian Regulatory Elements <i>in Vivo</i> ," <i>J. Biol. Chem.</i> 264(29):16985-16987.		
208.	Wu, G.Y. et al. (August 5, 1991). "Receptor-Mediated Gene Delivery <i>in Vivo</i> : Partial Correction of Genetic Analbuminemia in Nagase Rats," <i>J. Biol. Chem.</i> 266(22):14338-14342.		
209.	Wu, G.Y. et al. (April 15, 1994). "Incorporation of Adenovirus into a Ligand-Based DNA Carrier System Results in Retention of Original Receptor Specificity and Enhances Targeted Gene		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

PA-1122543

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/529,835
				Filing Date	(Intl.) October 6, 2003
				First Named Inventor	David L. SHELTON
				Art Unit	1644
				Examiner Name	Not Yet Assigned
Sheet	9	of	9	Attorney Docket Number	514712000300

		Expression," <i>J. Biol. Chem.</i> 269(15):11542-11546.	
	210.	Zenke, M. et al. (May 1990). "Receptor-Mediated Endocytosis of Transferrin-Polycation Conjugates: An Efficient Way to Introduce DNA Into Hematopoietic Cells," <i>Proc. Natl. Acad. Sci. USA</i> 87:3655-3659.	
	211.	Zheng, Z-J. et al. (October 30, 2001). "Sudden Cardiac Death in the United States, 1989 to 1998," <i>Circulation</i> 104:2158-2163.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

PA-1122543